齐鲁医院副院长刘新宇表示，他们将发挥现有优势医疗资源效能，带动辐射莱州市中医医院(市慢性病防治院)共同发展，进一步 推进专家技术力量帮扶支持，完善健全合作模式，实现优质医疗资源下沉。莱州市卫健局党组书记、局长吕俊峰表示，通过山 东大学齐鲁医院对市中医医院(市慢性病防治院)的真帮实扶，医院的学科建设一定会得到质的提升，管理能力、服务水平一定会 实现新的跨越。莱州市中医医院(市慢性病防治院)党委书记徐智诚强调，医院将牢牢把握新机遇，在各位专家的指导下，以学科 建设和人才队伍建设为核心，虚心学习、认真求教，不断深化拓展合作成效，提升诊疗能力，让广大群众不出莱州就能享受到 省级专家的医疗服务。 仪式上，与会领导共同为"山东大学齐鲁医院分级诊疗合作单位"和"山东大学齐鲁医院骨科工作站"揭牌。 7月9日，山东大学齐鲁医院分级诊疗合作单位暨山东大学齐鲁医院骨科工作站揭牌仪式在莱州市中医医院(市慢性病防治院)举 行。山东大学齐鲁医院副院长刘新宇，关节外科副主任卢群山，运动医学科主任王呈，脊柱外科主任医师刘海春，脊柱外科副 主任医师武文亮等参加活动。仪式由莱州市卫健局党组书记、局长吕俊峰主持。 武文亮副主任医师 山东大学齐鲁医 ...

Core Insights - Vand Investment recently conducted research on Sanbo Brain Science, highlighting the company's success in the world's first interventional brain-computer interface trial for restoring motor function in patients [1] - The company is expanding its network with new hospital branches in Beijing, Kunming, Xi'an, and Hunan, aiming to enhance medical service capabilities [1] - Sanbo Brain Science is focusing on a nationwide chain operation model and plans to establish over ten group-controlled hospitals while strengthening technological innovation and research成果转化 [1] Company Developments - The chairman's personal reasons do not affect the company's operations [1] - The company has a well-established talent training system, with medical personnel in local hospitals being recruited locally and trained in Beijing [1] - The proportion of medical insurance income varies by region, with Beijing's Sanbo Brain Science having about 30% of its income from insurance, while most out-of-town hospitals exceed this figure [1] Financial Performance - New hospital branches have different ramp-up periods, with Fujian Sanbo typically reaching breakeven in about three years, while Henan Sanbo is expected to improve its operational status in the future [1] - The company has repurchased shares for employee stock ownership plans and will implement this at an appropriate time [1] Market Context - The aging population is leading to an increase in degenerative diseases, particularly in the cardiovascular and neurological sectors, which will influence the company's future business growth [1] - The patient demographic spans a wide age range, from newborns to nonagenarians, with patient sources including reputation, technical training, and local expert collaborations [1] - The company actively fulfills social responsibilities through free clinics, discipline construction, and establishing brain health communities [1] Regulatory Environment - Short-term impacts from medical insurance policies are minimal, but long-term contributions to revenue are expected [1] - The DRG (Diagnosis-Related Group) single disease payment system has varying impacts on different hospital branches [1] - The application of brain-computer interfaces is still in the preliminary experimental verification stage, with more mature applications in neuroregulation for treating elderly Parkinson's disease and epilepsy [1]

证券代码：603716 证券简称：塞力医疗 公告编号：2025-061 债券代码：113601 债券简称：塞力转债 公司已按照《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所股票上市规则》 《上市公司募集资金监管规则》等法律法规的要求，制定了《募集资金管理办法》。根据公司的募集资 金管理制度，公司及子公司开设了专门的银行账户对募集资金进行专户存储，并与信达证券股份有限公 司及各开户行分别签署《募集资金专户存储三方监管协议》或《募集资金专户存储四方监管协议》。 （二）募集资金专户开立情况 公司及子公司2018年非公开发行募集资金在专项账户的存续及注销情况如下： 一、2018年非公开发行A股股票募集资金基本情况 经中国证券监督管理委员会核发的《关于核准武汉塞力斯医疗科技股份有限公司非公开发行股票的批 复》（证监许可[2017]2322号）核准，塞力斯医疗科技集团股份有限公司（以下简称"公司"）于2018年 6月5日非公开发行A股股票26,853,709股，每股面值1元，发行价格为每股人民币23.31元，募集资金总额 为625,959,956.79元，扣除各项发行费用后实际募集资金净额人民币607, ...

Core Viewpoint - Shenzhen Shangrong Medical Co., Ltd. announced a cash dividend distribution plan for the fiscal year 2024, with a total cash dividend of 6,755,714.22 yuan (including tax), distributing 0.08 yuan per 10 shares to shareholders [1][2][3]. Summary by Sections Dividend Distribution Plan - The company will distribute a cash dividend of 0.08 yuan per 10 shares, based on a total share count of 844,464,278 shares after excluding 1,030,300 shares held in the repurchase account [1][2][3]. - The total cash dividend amount is expected to be 6,755,714.22 yuan (including tax) [1][2]. Share Count and Adjustments - The total share count remains unchanged post-distribution, but the cash dividend per share will decrease due to the exclusion of repurchased shares [2][3]. - The calculation for the ex-dividend price will be based on the total share count, including repurchased shares, resulting in an adjusted price of approximately 0.079902 yuan per share [2][3][6]. Key Dates - The record date for the dividend distribution is set for July 17, 2025, and the ex-dividend date is July 18, 2025 [3][4]. Dividend Recipients - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [4][5]. Payment Method - Cash dividends will be directly credited to shareholders' accounts through their custodial securities companies or other custodial institutions [6].

Group 1 - The technology opens new avenues for treating refractory mental illnesses, including treatment-resistant depression, obsessive-compulsive disorder, and tic disorders [1][3] - A case study from Ruijin Hospital highlights a 32-year-old patient with a 16-year history of depression who benefited from a novel therapy combining deep brain stimulation (DBS) and brain-computer interface (BCI) technology [1] - The innovative treatment involves the implantation of two electrodes with 16 stimulation contacts into the brain's emotional circuit, allowing for precise modulation and breaking the cycle of depression [1][3] Group 2 - The DBS combined with BCI technology is a minimally invasive intervention that avoids the memory loss associated with electroconvulsive therapy and the side effects of long-term medication [3] - This new therapy has already been clinically applied to over 30 cases, providing a new option for treatment-resistant depression patients [3] - Depression is increasingly recognized as a significant mental health issue, particularly among younger populations, with a reported prevalence of 15% to 20% among adolescents in China [3]

Group 1 - The report emphasizes the need to regulate low-price disorderly competition among enterprises and promote the orderly exit of backward production capacity, aiming to address the issue of "involution" in market competition [2][8] - Historical cases show that supply-side clearance driven by policy typically begins with market expectations, while the main upward trend requires improvements in industry structure to support cash flow and balance sheet recovery [8][10] - The current round of overcapacity is primarily concentrated in mid- and downstream industries, unlike the previous cycle which was focused on upstream resource sectors [9][10] Group 2 - The report suggests focusing on two main strategies: industries that have experienced prolonged supply-side clearance and are likely to see improvements in supply-demand dynamics, and industries that may benefit from policy-driven accelerated clearance [10][11] - For natural clearance, the report recommends monitoring demand-side indicators for upstream industries and supply-side indicators for mid- and downstream sectors, highlighting sectors such as agricultural chemicals, general machinery, pharmaceuticals, and components [10] - For policy-driven clearance, attention should be given to industries mentioned in recent policies aimed at addressing "involution," including photovoltaic, lithium batteries, automobiles, and cement [10][17]

Core Viewpoint - The existence of functional lymphatic vessels in the meninges has been confirmed, leading to the emergence of a therapy called "Lymphatic-Venous Anastomosis" (LVA), aimed at clearing toxic proteins from the brain to halt the progression of Alzheimer's disease and preserve cognitive function [1][4]. Regulatory Actions - The National Health Commission has issued a notice prohibiting the use of LVA for treating Alzheimer's disease, citing that the technique is still in the early exploratory stage of clinical research, with unclear indications and contraindications, and lacking high-quality evidence for safety and efficacy [1][2]. Clinical Research and Observations - Clinical trials for LVA have been conducted in two hospitals in Shanghai, with 12 patients undergoing the procedure as of June 10, 2024. Initial feedback indicates slight improvements in cognitive abilities, particularly in attention and reaction speed, with some patients experiencing temporary mental confusion post-surgery [4][5]. Expert Opinions - Some experts express skepticism about the effectiveness of LVA, suggesting that the immediate post-operative improvements may be misleading and not indicative of long-term benefits. Concerns have been raised regarding the complexity of Alzheimer's disease and the simplicity of the surgical approach [5][6][7]. Alternative Applications - LVA has also been explored for treating Parkinson's disease, with some hospitals reporting its use as an alternative to traditional deep brain stimulation methods. However, the primary treatment for Parkinson's remains deep brain stimulation [5].

Market Performance - A-shares experienced fluctuations with the Shanghai Composite Index briefly surpassing the 3500-point mark, reaching a new high for the year before closing lower at 3493.05 points, down 0.13% [1] - The Shenzhen Component Index closed at 10581.80 points, down 0.06%, while the ChiNext Index rose 0.16% to 2184.67 points [1] - The total trading volume in the Shanghai and Shenzhen markets reached 15052 billion yuan, an increase of 512 billion yuan compared to the previous day [1] Sector Performance - The majority of industry sectors saw declines, with multi-financial, engineering consulting services, cultural media, medical services, and banking sectors leading in gains [1] - Conversely, the insurance, small metals, precious metals, shipbuilding, and wind power equipment sectors experienced significant declines [1] - More than 1800 stocks rose while over 3300 stocks fell, indicating a broader market weakness despite some sector gains [1] Analyst Outlook - Brokerages generally hold an optimistic view for the market, with Everbright Securities suggesting that a sustained breakthrough above 3500 points could enhance market sentiment and attract more capital [2] - CITIC Securities anticipates a trend towards easing in US-China tariff negotiations, which may alleviate market pressures [2] - The market is expected to enter a performance disclosure period in July, with a focus on sectors showing strong interim results, indicating potential investment opportunities [2] - The market is projected to maintain a fluctuating upward trend in early to mid-July, with technology remaining a key focus, though caution is advised regarding high valuation corrections [2]

Core Viewpoint - The article emphasizes the importance of establishing and managing health weight management clinics in response to the "Healthy China 2030" strategy, aiming to provide high-quality weight management services to the public [5][6][8]. Group 1: Establishment and Management of Clinics - The article outlines the requirement for various hospitals, including tertiary general hospitals and children's hospitals, to set up health weight management clinics by June 2025, aiming for full coverage [5]. - Hospitals are encouraged to coordinate resources effectively and involve multiple specialties such as pediatrics, nutrition, and psychology in the management of weight-related issues [5][6]. Group 2: Service Optimization - It is recommended that hospitals enhance their promotional efforts and improve appointment systems to guide individuals with weight management needs to specialized clinics [6]. - A classification service principle is suggested, providing tailored weight management plans for specific groups such as the elderly, children, and pregnant women [6]. Group 3: Quality Improvement - Hospitals are urged to strengthen their professional workforce, clarify roles, and enhance training to improve the quality of weight management services [7]. - The establishment of a quality control system for weight management services is encouraged, along with the integration of technology for monitoring and health guidance [7]. Group 4: Policy Support - Local health departments are called to provide policy and technical support for the development of weight management clinics, ensuring effective internal management within hospitals [8]. - Public health education is emphasized to improve the community's understanding of weight management, fostering a supportive social environment [8].

Summary of Key Points Core Viewpoint - The stock of Sely Medical (603716) experienced a significant increase of 9.86% on the trading day, with a turnover rate of 41.30% and a total transaction value of 1.799 billion yuan, indicating strong market interest and trading activity [2]. Trading Activity - The stock was listed on the Shanghai Stock Exchange's "龙虎榜" due to a daily turnover rate of 40.85%, with a net buying amount of 6.0667 million yuan from brokerage seats [2]. - The top five brokerage seats accounted for a total transaction value of 464 million yuan, with a buying transaction value of 235 million yuan and a selling transaction value of 229 million yuan, resulting in a net buying of 6.0667 million yuan [2]. - The largest buying and selling brokerage was Guotai Junan Securities Co., Ltd. headquarters, with buying amounting to 69.4307 million yuan and selling amounting to 95.7336 million yuan [2]. Historical Performance - Over the past six months, the stock has appeared on the "龙虎榜" 23 times, with an average price increase of 0.93% the day after being listed and an average increase of 3.90% over the following five days [2]. Capital Flow - On the trading day, the stock saw a net inflow of 242 million yuan from major funds, with a net inflow of 171 million yuan from large orders and 70.8008 million yuan from medium orders [2]. - In the past five days, the net inflow of major funds totaled 85.3307 million yuan [2]. Financial Performance - According to the Q1 report released on April 29, the company achieved a revenue of 287 million yuan, representing a year-on-year decline of 40.75%, and reported a net loss of 14.3209 million yuan [2].